Effect of glimepiride versus teneligliptin in combination with metformin in type 2 diabetes mellitus patients

Effect of glimepiride versus teneligliptin in combination with metformin in type 2 diabetes mellitus patients Razia Abdul Rasheed Department of Pharmacology, Melmaruvathur Adhiparasakthi Institute of Medical Sciences and Research, Chengalpattu, Tamil Nadu, India G. Venkatraman Department of Orthopaedics, Vels Medical College and Hospital, Tiruvallur, Tamil Nadu, India S. Vijayalakshmi Department of Pharmacology, Melmaruvathur Adhiparasakthi Institute of Medical Sciences and Research, Chengalpattu, Tamil Nadu, India T. A. R. Raja Department of Pharmacology, Melmaruvathur Adhiparasakthi Institute of Medical Sciences and Research, Chengalpattu, Tamil Nadu, India G. Senthil Department of Pharmacology, Melmaruvathur Adhiparasakthi Institute of Medical Sciences and Research, Chengalpattu, Tamil Nadu, India P. Renugadevi Department of Pharmacology, Melmaruvathur Adhiparasakthi Institute of Medical Sciences and Research, Chengalpattu, Tamil Nadu, India Abstract BACKGROUND:

Long-term metabolic disease type 2 diabetes mellitus (T2DM) is distinguished by elevated blood glucose, insulin resistance, and drought of insulin with dyslipidemia. Oral hypoglycemic agents lower blood glucose levels as well as prevent both short-term and long-term complications such as micro/macrovascular atherosclerosis, chronic kidney diseases, and chronic heart disease. This study aims to compare the effect of glimepiride versus teneligliptin in combination with metformin in T2DM patients attending a tertiary care hospital.
MATERIALS AND METHODS:

This prospective, randomized, open-label study was initiated in a tertiary care hospital after obtaining IEC approval. Written informed consent was obtained. The sample size was calculated using “Statistics and sample size software.” Ninety-seven patients satisfying the inclusion criteria were assigned to two groups using simple randomization with allocation 1:1. Group A received metformin + glimepiride while Group B received metformin + teneligliptin for 12 weeks. Fasting blood sugar (FBS), postprandial blood sugar (PPBS), glycated hemoglobin (HbA1c), and lipid profile were recorded at the baseline and at the end of 12 weeks. This study was conducted for 1 year. Data were analyzed using SPSS version 23.0 software.
RESULTS:

Out of 97 participants (Group A: 48 and Group B: 49), Group A showed a higher reduction in FBS (48.18 ± 9.64) whereas Group B showed 72.53 ± 5.01, 1.74 ± 0.42 of change in PPBS and HbA1c after 12 weeks.
CONCLUSION:

The study found that combining metformin with teneligliptin was better tolerated and improved glycemic control and lipid profile compared to metformin plus glimepiride.
09 2024 12 16 2024 317 321 1 10.1097/LWW.0000000000001000 lww.com ovid.com true 2024-02-06 2024-10-24 http://creativecommons.org/licenses/by-nc-sa/4.0 10.4103/ijp.ijp_107_24 https://journals.lww.com/10.4103/ijp.ijp_107_24 https://journals.lww.com/10.4103/ijp.ijp_107_24 AORN J Bailes 76 266 2002 10.1016/S0001-2092(06)61065-X Diabetes mellitus and its chronic complications Nurs Stand Cloete 37 61 2022 10.7748/ns.2021.e11709 Diabetes mellitus: An overview of the types, symptoms, complications and management Biomed Pharmacother Padhi 131 110708 2020 10.1016/j.biopha.2020.110708 Type II diabetes mellitus: A review on recent drug based therapeutics Diabetologia Sanchez-Rangel 60 1586 2017 10.1007/s00125-017-4336-x Metformin: Clinical use in type 2 diabetes Curr Top Med Chem Lv 20 37 2020 10.2174/1568026620666191224141617 Mechanisms and characteristics of sulfonylureas and glinides Front Endocrinol (Lausanne) Gilbert 11 178 2020 10.3389/fendo.2020.00178 GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: Review of head-to-head clinical trials Front Pharmacol Li 9 449 2018 10.3389/fphar.2018.00449 Efficacy and safety of teneligliptin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials Int J Adv Pharm Biol Chem Abhijeet 5 1679 2017 Effect of teneligliptin supplementation as add on therapy to metformin in uncontrolled type 2 diabetes mellitus Diabetes Ther Kim 12 2907 2021 10.1007/s13300-021-01148-1 Efficacy and safety of switching to teneligliptin in patients with type 2 diabetes inadequately controlled with dipeptidyl peptidase-4 inhibitors: 52-week results from a prospective observational study Diabetes Care 44 S15 2021 10.2337/dc21-S002 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2021 Indian J Endocrinol Metab Kalra 19 577 2015 10.4103/2230-8210.163171 Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement Diabetes Metab Syndr Obes Sharma 9 251 2016 10.2147/DMSO.S106133 Teneligliptin in management of type 2 diabetes mellitus Diabetes Obes Metab Kim 21 631 2019 10.1111/dom.13566 Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial Diabetes Obes Metab Kim 16 900 2014 10.1111/dom.12293 Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: A systematic review and meta-analysis Vasc Health Risk Manag Basit 8 463 2012 10.2147/VHRM.S33194 Glimepiride: Evidence-based facts, trends, and observations (GIFTS). [Corrected] Curre Res Diabetes Obes J Parmar 13 555869 2020 Efficacy and safety of teneligliptin as add on therapy in Indian type 2 diabetes mellitus T2DM patients having dyslipidemia Int J Res Med Sci Patil 8 692 2020 10.18203/2320-6012.ijrms20200258 A study of effectiveness of addition of drug teneligliptin to metformin, glimepiride, pioglitazone combination in type II diabetic patients Int J Adv Med Raghavan 6 481 2019 10.18203/2349-3933.ijam20191163 Effect of teneligliptin versus metformin on glycemic control in Indian patients with newly-diagnosed, drug-naïve type 2 diabetes mellitus: A 12-week randomized comparative clinical study Mol Metab Baumeier 6 1254 2017 10.1016/j.molmet.2017.07.016 Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease Int J Pharm Sci Res Nishanth 9 5258 2018 A study to compare efficacy of metformin-glimepiride versus metformin-teneligliptin in type II diabetic patients Endocrinol Diabetes Metab Ji 4 e00222 2021 10.1002/edm2.222 Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double-blind, placebo-controlled study Clin Drug Investig Fujita 37 219 2017 10.1007/s40261-016-0478-8 Factors related to the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors: A systematic review and meta-analysis focusing on ethnicity and study regions Clin Pharmacol Ther Ito 102 701 2017 10.1002/cpt.692 Ethnic difference in the pharmacodynamics-efficacy relationship of dipeptidyl peptidase-4 inhibitors between Japanese and non-Japanese patients: A systematic review Diabetologia Kim 56 696 2013 10.1007/s00125-012-2827-3 Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: A systematic review and meta-analysis